Please use this identifier to cite or link to this item:
|Title:||Inhibitors of topoisomerases as anticancer drugs: Problems and prospects|
|Authors:||Dwarakanath, B S|
|IPC Code:||Int Cl7 A61 K|
|Abstract:||DNA topoisomerases, which solve topological problems associated with various DNA transactions, are the targets of many therapeutic agents. Various topoisomerase inhibitors especially, topo-poisons, camptothecin (topo-I) and etoposide (topo-II) are some of the drugs that are used in the current treatment protocols, particularly for the treatment of leukemia (AML, ALL etc). However, tumor resistance, normal and non-specific tissue cytotoxicity are the limitations for successful development of these drugs as one of the primary therapeutic agents for the treatment of tumors in vitro. This brief review presents the current understanding about cytotoxicity development and outlines various approaches to overcome the limitations for enhancing the efficacy of topo-poison based anticancer drugs.|
|ISSN:||0975-1009 (Online); 0019-5189 (Print)|
|Appears in Collections:||IJEB Vol.42(07) [July 2004]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.